Quick Answer
Arcturus Therapeutics Holdings Inc. reported Total Revenue of $82.03 million for the year ending 2025.
- Arcturus Therapeutics Holdings Inc. showed a decrease of -46.1% in Total Revenue from 2024 to 2025.
- This data is from Arcturus Therapeutics Holdings Inc.'s annual report (Form 10-K), filed with the SEC on March 3, 2026.
- XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2018: $2.39 million | Q3 2018: $3.42 million | Q1 2019: $4.35 million | Q2 2019: $10.15 million | Q3 2019: $3.32 million | Q4 2019: $2.97 million | Q1 2020: $2.65 million | Q2 2020: $2.32 million | Q3 2020: $2.33 million | Q4 2020: $2.24 million | Q1 2021: $2.13 million | Q2 2021: $2.00 million | Q3 2021: $2.44 million | Q4 2021: $5.79 million | Q1 2022: $5.24 million | Q2 2022: $27.09 million | Q3 2022: $13.37 million | Q1 2023: $80.29 million | Q2 2023: $10.52 million | Q3 2023: $45.14 million | Q1 2024: $38.01 million | Q2 2024: $49.86 million | Q3 2024: $41.67 million | Q1 2025: $29.38 million | Q2 2025: $28.30 million | Q3 2025: $17.15 million.
- Over the full 8 years of available data (2018 to 2025), Arcturus Therapeutics Holdings Inc.'s Total Revenue has grown by 420.7%.
- Historical annual values: Fiscal year 2025: $82.03 million | Fiscal year 2024: $152.31 million | Fiscal year 2023: $166.80 million | Fiscal year 2022: $206.00 million | Fiscal year 2021: $12.36 million | Fiscal year 2020: $9.54 million | Fiscal year 2019: $20.79 million | Fiscal year 2018: $15.75 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: